Lutz B. Giebel

Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies

IpiNovyx Bio, Inc. is a drug development and platform technology company that focuses on developing novel therapeutics to treat autoimmune and inflammatory diseases through selective inhibition of the immunoproteasome. The company is based in West Nyack, NY. The company's platform technology enables highly selective, reversible, and non-toxic inhibition of various immune cell types, with applications across a range of indications with underlying immunopathology. Orange Grove Bio (OGB) is an emerging, preclinical, capital allocation, and asset development biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company was founded by Jim Graham, and the CEO is Marc Appel.

Orange Grove Bio LLC is a preclinical biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company is based in Cincinnati, OH. The company fosters strong relationships with entrepreneurs and technology transfer offices outside of the traditional medical technology hubs. Orange Grove Bio's team possesses more than one hundred years of drug development and company creation experience, allowing it to build and finance innovative programs from the research and development stage to clinical trials. The company was founded by Marc Appel. Marc Appel has been the CEO since incorporation.

Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom.

Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.